

NIH Institutional Biosafety Committee Minutes
Location: Rocky Mountain Laboratories

March 19, 2026

1:00 PM – 3:00 PM

Virtual via Microsoft Teams/In person at Building A Room 322

Members Present:

Quorum Met: Yes

☒	Sue Priola	Chair	☐	Alida Merritt	Local Non-Affiliated
☐	Andrea Marzi	Vice Chair	☐	Alexandra Scranton	Member
☒	Rebecca Anderson	Biosafety Officer	☒	Clayton Winkler	Lab Representative
☒	Paul Beare	Lab Representative	☒	Todd Wohlman	Member
☒	Chris Bosio	Lab Representative	☐	Sonja Best	Ex officio
☐	Megan Brose	Member	☐	Marshall Bloom	Ex officio
☐	Larry Brouwer	Local Non-Affiliated	☐	Marcie Caldwell	Ex officio
☒	Chad Clancy	Animal Expert	☐	Frank DeLeo	Ex officio
☐	Erik Hoover	Local Non-Affiliated	☐	Heinz Feldmann	Ex officio
☒	Scott Kobayashi	Lab Representative	☐	Josh Kellar	Ex officio
☐	Jamie Lovaglio	Animal Expert	☐	Brian Vickrey	Ex officio

Guests Present:

Jared Montana, Shanda Sarchette, Michael Kujawa, Richard Baumann, David Bland, Chris McGee, Karin Peterson, Adrienne Glaser, Rachel Feldman

Announcements & Call to Order

- I. Meeting called to order by Sue Priola at 1:01 pm.
- II. The IBC Chair reminded all members present to identify any conflicts of interest as each registration is reviewed.

Review of Past IBC Meeting Minutes

- I. February 19th, 2026 Minutes
 - a. Comments on minutes
 - i. No comments
 - b. The minutes were unanimously approved with minor modifications.

New Committee Business

- I. BSO or IBC lead reviewer preliminary registration approvals since the previous meeting
 - a. Pathogen only Registration Numbers – None
 - b. rDNA and rDNA/pathogen Registration Numbers: None
 - c. Registration amendments summary: None
 - d. Committee Discussion: None
- II. Registrations for Committee review

a. Registrations for committee review:

Karin Peterson, 26-RML-003

- i. Reviewers: Not applicable; No recombinant DNA work
- ii. Review Summary and risk assessment: The PI, Karin Peterson and her post doc presented a summary of their proposed work and how they will work with mosquitoes. This is new work for RML, the mosquitoes will be worked with in the new insectary in the new vivarium on campus. Becky Anderson informed the committee that the Peterson lab has been working with biosafety to develop their SOP and setup the mosquito wing of the insectary. The Peterson lab will initially start with rearing mosquitoes and gain experience working with uninfected mosquitoes. Once the colony and procedures are established, the Peterson lab will submit an amendment to the IBC to add infectious work. This will be a slow process to make sure all work is performed safely.
- iii. Committee Discussion: A committee member asked if the eggs that they will be receiving from their collaborator will be screened for pathogens before receipt. The PI said they can make sure screening is performed before obtaining the eggs, this language can be added to the arthropod section of the registration. The committee also requested the PI ensure that thicker gowns are used in the insectary for a more robust protection layer over the street clothes. Becky Anderson said she can work with RMVB to make sure the supplied PPE is appropriate. It was also noted that in the PPE section, the box for coveralls needs to be checked.
- iv. Minimum PPE required special practices, and recommended OMS consult if applicable: Disposable gloves, disposable gown or coveralls, eye protection and face mask (if potential for splashes)
- v. Training:
 1. Laboratory safety training (includes BBP training)
 2. Training by the insectary manager
- vi. Animal studies proposed: No.
- vii. The committee discussed the dual-use and ePPP potential of these experiments. The committee agreed that there were no dual-use or ePPP concerns with the proposal.
- viii. Work is approved at BSL-2/ACL2
- ix. Relevant sections of the NIH Guidelines: Not applicable; no recombinant work
- x. A motion was made to approve the registration pending the following changes or conditions.
 1. Add to the arthropod section that the eggs will be screened for pathogens.
 2. Add coveralls to the list of PPE.
- xi. The committee approved (Clayton Winkler abstained) with minor modifications.
 1. Conflicts of Interest: None
 2. Votes for: 7 Votes against: 0 Abstained: 1

a. Registration amendments for committee review:

- i. None.

III. Committee Review of Inactivation Procedures (if not reviewed under a registration)

- a. *Burkholderia spp.* inactivation validation with 4% PFA for Carrie Long.

- i. Inactivation procedure summary: The lab validated an inactivation protocol using 4% PFA on *Burkholderia thailandensis* infected cells. The appropriate controls were included and yielded the expected results. All test samples were negative by growth on Mueller Hinton plates and TSB overnight cultures.
 - ii. Committee Discussion: The committee discussed the experimental design. The committee questioned the written description of the final assay. It was not clear if samples were grown on MMH plates first and then TSB overnight cultures or if they were tested separately. This detail needs to be clarified.
 - xii. A motion was made to approve the procedure pending the following changes or conditions.
 - 1. Clarify the use of MMH plates and TSB overnight cultures for the readout.
 - iii. The committee unanimously approved as written.
 - 1. Conflicts of Interest: None
 - 2. Votes for: 8 Votes against: 0 Abstained: 0
- b. *Burkholderia spp.* inactivation validation with lysis buffer and boiling for Carrie Long.
 - i. Inactivation procedure summary: The lab validated an inactivation protocol using lysis buffer and boiling on *Burkholderia thailandensis* infected cells. The appropriate controls were included and yielded the expected results. All test samples were negative by growth in TSB overnight cultures. The not boiled samples in lysis buffer also did not grow due to the nature of the lysis buffer.
 - ii. Committee Discussion: The committee discussed the experimental design. The committee questioned the use of TSB overnight cultures alone as a readout. It was not clear what qualifies as a positive vs negative sample in this assay and what the limit of detection is for TSB overnight cultures. The committee wants the PI to repeat the experiment by removing the lysis buffer, which can be accomplished by using a column or dialyzing the samples.
 - iii. The committee tabled the inactivation validation.
 - 1. PI is requested to repeat the experiment with a readout that allows for clear interpretation of positive and negative controls. The PI should also consider removing the lysis buffer prior to assaying for effectiveness of inactivation.

IV. Standard Operating Procedures/Plans

- a. BSL-3 Suite A
 - i. SOP Summary: The update was to add the new inactivation procedures with 4% PFA and lysis buffer plus boiling for *Burkholderia pseudomallei*.
 - ii. Committee Discussion: The committee agreed the SOP could be approved for the 4% PFA inactivation, but the lysis buffer plus boiling could not be approved.
 - iii. A motion was made to approve the procedure for 4% PFA only.
 - iv. The committee unanimously approved as written.
 - 1. Conflicts of Interest: None
 - 2. Votes for: 8 Votes against: 0 Abstained: 0
- b. ABSL-2 Mosquito Operations and Safety Procedures
 - i. SOP Summary: This is a new SOP for the establishment of a mosquito colony at RML in the new insectary. The SOP describes all procedures related to handling mosquitos as well as spill and escaped mosquito procedures. The establishment of this SOP is the first step for the Peterson lab to get started with the mosquito colony at RML.

- ii. Committee Discussion: The committee asked if there are mirrors in the insectary so you can visually check yourself prior to exit. The PI stated that there are mirrors and agreed this could be added to the SOP. The committee asked the PI to add face masks for PPE whenever there is potential for splashes. It was also noted that 70% ethanol should be included in the list of items for the escaped mosquito kits. A couple of minor typos were also noted.
- xiii. A motion was made to approve the procedure pending the following changes or conditions.
 - 1. Add mention of mirrors to the SOP
 - 2. Add face masks to the list of PPE when there is potential for splashes.
 - 3. Add 70% ethanol to the list of items for the escaped mosquito kit.
 - 4. Correct minor typos
- iii. The committee unanimously approved as written.
 - 1. Conflicts of Interest: None
 - 2. Votes for: 8 Votes against: 0 Abstained: 0

- V. Serious Adverse Events in Clinical Trials reviewed by the Committee
 - a. N/A

Reports

- I. Biosafety Officer Report – See attached

Around the Room/Committee Discussion

- I. None

Adjournment

- I. Meeting adjourned by Sue Priola at 02:08 pm

Next Meeting

- I. Scheduled April 16th, 2026.

NIH RML Institutional Biosafety Committee Meeting

Biosafety Officer (BSO) Report

March 19, 2026

Business Conducted since the last IBC Meeting

- A. BSO approvals
 - a. None
- B. Electronic business
 - a. None

New business for IBC meeting

- A. See agenda.

Division of Safety activities since the last IBC Meeting

- A. Animal Study Protocols Review- Performed by Division of Safety staff
 - a. 4 ASPs reviewed since the last IBC meeting.
- B. Biosafety Training- Performed by Division of Safety staff

Type of Training	Number of Sessions	Number of Employees Trained
New Employee	n/a	n/a
Annual Refresher Lab Biosafety	n/a	n/a
Select Agent-Initial	1	1
Select Agent- Refresher	n/a	n/a
Select Agent- Visitor	1	1
BSL-3 Laboratory Biosafety-Initial	1	1
Practical Training	n/a	n/a
BSL-4 Laboratory Biosafety-Initial	n/a	n/a
Suit Training	3	3
Checklist Training	6	2
BSL-4 Laboratory Biosafety-Refresher & SA Refresher	n/a	n/a
Laboratory Biosafety Support Staff-Initial	1	1
Laboratory Biosafety Support Staff-Refresher & SA Refresher	n/a	n/a
BSL-4 Medical Emergency Egress Training	n/a	n/a

- C. Biological Incidents to Report
 - a. None.
- D. Other Updates
 - a. Remote FSAP Inspection was February 24-26th, 2026. An unannounced inspection will occur within 4-8 weeks of the remote inspection.
 - b. Draft guidance document, IBC Guidance for Registrations Covering SARS-CoV-2 Work
 - i. Will be reviewed by the DURC-IRE and NIH leadership prior to implementation